Orexo: Zubsolv Rx Data week 1, 2017

According to latest Symphony Health Solutions Rx data, Zubsolv tablets showed a market share of 5.69% (5.78%), 4-week rolling average. The total number of Zubsolv tablets sold week 1 (52) reaching 304,453 (290,099). Zubsolv prescriptions (TRx) recorded a market share of 5.61% (5.67%), 4-week rolling average. Total number of prescriptions reaching 11,084 (10,276) during the week. The overall market (buprenorphine/naloxone) showed a y/y growth rate of 8.6% (10.9%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 8.2% (9.6%) (4-week rolling average).

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-02-24 Update
2017-02-24 Update
2017-02-24 Update
2017-02-24 Update
2017-02-22 Update
2017-02-22 Update
2017-02-20 Update
2017-02-20 Update
2017-02-20 Analys
2017-02-20 Update
2017-02-17 Update
2017-02-17 Update
2017-02-17 Update
2017-02-16 Update
2017-02-16 Update
2017-02-16 Update
2017-02-13 Update
2017-02-13 Update
2017-02-13 Update
2017-02-10 Update
2017-02-10 Update
2017-02-10 Update
2017-02-03 Update
2017-02-03 Analys
2017-02-01 Update